Logo.jpg
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
31 oct. 2024 08h30 HE | Elicio Therapeutics Inc.
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1...
Logo.jpg
Elicio Therapeutics Reports Inducement Grants
16 oct. 2024 08h30 HE | Elicio Therapeutics Inc.
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics Reports Inducement Grants
17 sept. 2024 08h31 HE | Elicio Therapeutics Inc.
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
13 sept. 2024 08h30 HE | Elicio Therapeutics Inc.
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
28 août 2024 08h00 HE | Elicio Therapeutics Inc.
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
13 août 2024 16h30 HE | Elicio Therapeutics Inc.
• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at...
Logo.jpg
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
12 août 2024 16h05 HE | Elicio Therapeutics Inc.
BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
28 juin 2024 09h00 HE | Elicio Therapeutics Inc.
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics Announces Proposed Public Offering
27 juin 2024 16h05 HE | Elicio Therapeutics Inc.
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Logo.jpg
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
27 juin 2024 16h01 HE | Elicio Therapeutics Inc.
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...